TIDMVAL

RNS Number : 4915X

ValiRx PLC

01 September 2020

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Total Voting Rights

London, UK 1 September 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company today updated its total voting rights disclosure position.

In conformity with DTR 5.6.1, the Company notifies that as at the date of this announcement, the total number of Ordinary Shares in issue will be 56,854,039. There are no Ordinary Shares held in treasury. Each Ordinary Share entitles the holder to a single vote at general meetings of the Company.

The figure of 56,854,039 Ordinary Shares may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

As announced on 28 August 2020, application has been made to the London Stock Exchange to admit the 250,000 new ordinary shares resulting from the Warrant Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 3 September 2020. The new ordinary shares will rank pari passu with the existing ordinary shares.

Following admission of the 250,000 new ordinary shares to trading on AIM on or around 3 September 2020, the Company's total issued share capital will comprise 57,104,039 ordinary shares of 0.1 pence each.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information please contact:

 
 ValiRx plc                                           Tel: +44 (0) 20 7073 
                                                                       2628 
                                                             www.valirx.com 
  Suzanne Dilly                                    Suzanne.Dilly@valirx.com 
 
   Cairn Financial Advisers LLP (Nominated             Tel: +44 (0) 20 7213 
   Adviser)                                                            0880 
   Liam Murray / Jo Turner / Ludovico Lazzaretti 
 
   Peterhouse Capital Limited (Sole Broker)            Tel: +44 (0) 20 7469 
   Duncan Vasey / Lucy Williams / Eran Zucker                          0930

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVREAFPPALAEEFA

(END) Dow Jones Newswires

September 01, 2020 02:00 ET (06:00 GMT)

Valirx (LSE:VAL)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Valirx Charts.
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Valirx Charts.